Controversially, in a cross-sectional study, insulin treatment was one of the risk factors for age-related muscle atrophy in those with diabetes [70], while in a longitudinal study, insulin treatment and correction of glycemic level attenuated the progression of sarcopenia [79]. The gene discussed is INS; the disease is sarcopenia.